Subacute thrombosis following implantation of zotarolimus-eluting stent.
Endeavor (Medtronic Europe SA) is a new zotarolimus-eluting stent with a favourable safety profile reported in early trials. We report a case of subacute thrombosis following deployment of an Endeavor stent in the distal left anterior descending coronary artery, despite optimum loading with and continuation of clopidogrel therapy as well as previous administration of a IIb/IlIa inhibitor.
Korovesis
Socrates
S
Department of Cardiology, Athens Euroclinic, Athens, Greece.
Giazitzoglou
Eleftherios
E
Katritsis
Demosthenes G
DG
D015906:Angioplasty, Balloon, Coronary; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects*; D020099:Coated Materials, Biocompatible / Q000009:adverse effects*; D017023:Coronary Angiography; D003328:Coronary Thrombosis / Q000000981:diagnostic imaging / Q000209:etiology* / Q000628:therapy; D004562:Electrocardiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000601:surgery*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D015607:Stents / Q000009:adverse effects*
D020099:Coated Materials, Biocompatible; C489443:zotarolimus; D020123:Sirolimus